ArticleCommunications medicine2025
A clinically validated AI framework for kidney cancer detection and characterization.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma is one of the most common cancers of the urinary tract and is usually diagnosed by interpreting contrast-enhanced computed tomography scans. Rising demand for radiological services, combined with a shortage of radiologists, makes timely and accurate diagnosis increasingly challenging. Automated approaches may help radiologists improve efficiency and accuracy.
methodsWe developed BMVision, a deep learning-based tool for detecting and characterizing kidney cancer. The tool integrates with a web-based viewer designed to provide an intuitive interface for radiologists. Its performance was evaluated in a two-stage retrospective reader study. Six radiologists independently reviewed 200 scans across both AI-assisted and unaided workflows, allowing comparison of diagnostic performance and workflow efficiency with and without support from the tool. Statistical analysis compared AI-aided and unaided workflows across predefined clinical criteria, including diagnostic sensitivity, lesion measurement, reporting efficiency, and inter-radiologist agreement, using non-parametric tests and bootstrapping.
resultsHere we show that BMVision reduces radiologists' reporting time by an average of 33%, up to 52%. The tool provides structured auto-generated reports, minimizing the need for manual dictation or typing. In addition, BMVision improves sensitivity for detecting benign renal lesions (from 79.9 to 86.3%) and leads to a significant increase in inter-radiologist agreement.
conclusionsTo the best of our knowledge, BMVision is the first clinically validated commercial artificial intelligence tool for kidney cancer detection and characterization. By improving diagnostic accuracy and reporting efficiency, it has the potential to enhance patient care and help radiologists meet the growing demand for high-quality cancer diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.